Last reviewed · How we verify
Colestimide (colestilan)
Colestimide works by inhibiting the absorption of cholesterol and/or phosphorus in the intestines.
Colestimide, also known as colestilan, is a small molecule drug developed by Tanabe Pharma Corporation. It is used to treat hyperlipidemia and hyperphosphatemia, and its exact mechanism of action is not well-documented. As a colestilan, it is likely involved in the inhibition of intestinal absorption of cholesterol and/or phosphorus. The commercial status of Colestimide is unclear, and it may be patented or available as a generic. Further research is needed to fully understand its safety and efficacy.
At a glance
| Generic name | colestilan |
|---|---|
| Also known as | BindRen |
| Sponsor | Tanabe Pharma Corporation |
| Drug class | colestilan |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | discontinued |
Mechanism of action
Think of it like a sponge that soaks up extra cholesterol and phosphorus from the food you eat, preventing it from entering your bloodstream and causing problems. This can help lower levels of cholesterol and phosphorus in your blood, which can reduce your risk of heart disease and other health issues. By reducing the amount of cholesterol and phosphorus in your blood, Colestimide can help improve your overall health and well-being.
Approved indications
- Hyperlipidemia
- Hyperphosphatemia
Common side effects
Key clinical trials
- A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia (PHASE3)
- Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia (PHASE3)
- A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia (PHASE3)
- A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in Patients With Hyperphosphatemia (PHASE3)
- Drug-Drug Interaction Study to Evaluate the Effect of Colestilan on the Pharmacokinetics of Single Doses of Candesartan Cilexetil in Healthy Subjects (PHASE1)
- Efficacy and Safety Study of MCI-196 Versus Simvastatin for Dyslipidaemia in Chronic Kidney Disease (CKD) Subjects on Dialysis (PHASE3)
- A Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia (PHASE3)
- Efficacy and Safety Study of MCI-196 in Patients With Type 2 Diabetes (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Colestimide CI brief — competitive landscape report
- Colestimide updates RSS · CI watch RSS
- Tanabe Pharma Corporation portfolio CI